Sugar-sweetened beverages, low/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project.
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
21 04 2023
21 04 2023
Historique:
received:
18
08
2022
accepted:
06
04
2023
revised:
30
03
2023
medline:
25
4
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
Sweetened beverage intake may play a role in non-alcoholic fatty liver disease (NAFLD) development, but scientific evidence on their role is limited. This study examined associations between sugar-sweetened beverages (SSB), low/no-calorie beverages (LNCB) and fruit juice (FJ) intakes and NAFLD in four European studies. Data for 42,024 participants of Lifelines Cohort, NQPlus, PREDIMED-Plus and Alpha Omega Cohort were cross-sectionally analysed. NAFLD was assessed using Fatty Liver Index (FLI) (≥60). Restricted cubic spline analyses were used to visualize dose-response associations in Lifelines Cohort. Cox proportional hazard regression analyses with robust variance were performed for associations in individual cohorts; data were pooled using random effects meta-analysis. Models were adjusted for demographic, lifestyle, and other dietary factors. Each additional serving of SSB per day was associated with a 7% higher FLI-defined NAFLD prevalence (95%CI 1.03-1.11). For LNCB, restricted cubic spline analysis showed a nonlinear association with FLI-defined NAFLD, with the association getting stronger when consuming ≤1 serving/day and levelling off at higher intake levels. Pooled Cox analysis showed that intake of >2 LNCB servings/week was positively associated with FLI-defined NAFLD (PR 1.38, 95% CI 1.15-1.61; reference: non-consumers). An inverse association was observed for FJ intake of ≤2 servings/week (PR 0.92, 95% CI: 0.88-0.97; reference: non-consumers), but not at higher intake levels. Theoretical replacement of SSB with FJ showed no significant association with FLI-defined NAFLD prevalence (PR 0.97, 95% CI 0.95-1.00), whereas an adverse association was observed when SSB was replaced with LNCB (PR 1.12, 95% CI 1.03-1.21). Pooling results of this study showed that SSB and LNCB were positively associated with FLI-defined NAFLD prevalence. Theoretical replacement of SSB with LNCB was associated with higher FLI-defined NAFLD prevalence. An inverse association was observed between moderate intake of FJ and FLI-defined NAFLD. Our results should be interpreted with caution as reverse causality cannot be ruled out.
Sections du résumé
BACKGROUND
Sweetened beverage intake may play a role in non-alcoholic fatty liver disease (NAFLD) development, but scientific evidence on their role is limited. This study examined associations between sugar-sweetened beverages (SSB), low/no-calorie beverages (LNCB) and fruit juice (FJ) intakes and NAFLD in four European studies.
METHODS
Data for 42,024 participants of Lifelines Cohort, NQPlus, PREDIMED-Plus and Alpha Omega Cohort were cross-sectionally analysed. NAFLD was assessed using Fatty Liver Index (FLI) (≥60). Restricted cubic spline analyses were used to visualize dose-response associations in Lifelines Cohort. Cox proportional hazard regression analyses with robust variance were performed for associations in individual cohorts; data were pooled using random effects meta-analysis. Models were adjusted for demographic, lifestyle, and other dietary factors.
RESULTS
Each additional serving of SSB per day was associated with a 7% higher FLI-defined NAFLD prevalence (95%CI 1.03-1.11). For LNCB, restricted cubic spline analysis showed a nonlinear association with FLI-defined NAFLD, with the association getting stronger when consuming ≤1 serving/day and levelling off at higher intake levels. Pooled Cox analysis showed that intake of >2 LNCB servings/week was positively associated with FLI-defined NAFLD (PR 1.38, 95% CI 1.15-1.61; reference: non-consumers). An inverse association was observed for FJ intake of ≤2 servings/week (PR 0.92, 95% CI: 0.88-0.97; reference: non-consumers), but not at higher intake levels. Theoretical replacement of SSB with FJ showed no significant association with FLI-defined NAFLD prevalence (PR 0.97, 95% CI 0.95-1.00), whereas an adverse association was observed when SSB was replaced with LNCB (PR 1.12, 95% CI 1.03-1.21).
CONCLUSIONS
Pooling results of this study showed that SSB and LNCB were positively associated with FLI-defined NAFLD prevalence. Theoretical replacement of SSB with LNCB was associated with higher FLI-defined NAFLD prevalence. An inverse association was observed between moderate intake of FJ and FLI-defined NAFLD. Our results should be interpreted with caution as reverse causality cannot be ruled out.
Identifiants
pubmed: 37085478
doi: 10.1038/s41387-023-00237-3
pii: 10.1038/s41387-023-00237-3
pmc: PMC10121594
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Subventions
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Organisme : European Commission (EC)
ID : 774293
Informations de copyright
© 2023. The Author(s).
Références
Br J Nutr. 2010 Jun;103(12):1808-16
pubmed: 20102675
Nutrition. 2020 Mar;71:110620
pubmed: 31838461
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Eur J Nutr. 2019 Aug;58(5):1759-1769
pubmed: 29761318
Eur J Nutr. 2021 Aug;60(5):2449-2467
pubmed: 33150530
Prev Chronic Dis. 2006 Oct;3(4):A118
pubmed: 16978493
Public Health Nutr. 2005 Oct;8(7):920-7
pubmed: 16277809
N Engl J Med. 2010 Nov 18;363(21):2015-26
pubmed: 20929341
Public Health Nutr. 2022 Feb;25(2):225-236
pubmed: 33988111
Am J Clin Nutr. 2011 Aug;94(2):479-85
pubmed: 21677052
Food Nutr Res. 2011;55:
pubmed: 21799667
JAMA Netw Open. 2020 Jul 1;3(7):e209993
pubmed: 32644139
PLoS One. 2015 Mar 17;10(3):e0120443
pubmed: 25781622
J Hepatol. 2018 May;68(5):1063-1075
pubmed: 29408694
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4
pubmed: 23353640
Am J Clin Nutr. 2014 Jul;100(1):65-79
pubmed: 24808490
BMC Med Res Methodol. 2009 Aug 10;9:58
pubmed: 19664254
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Physiol Behav. 2016 Oct 1;164(Pt B):446-450
pubmed: 27039282
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Eur J Clin Nutr. 2019 Dec;73(12):1556-1560
pubmed: 31636410
PLoS One. 2015 Sep 02;10(9):e0137203
pubmed: 26333164
Public Health Nutr. 2010 Sep;13(9):1364-72
pubmed: 20105389
J Gastroenterol Hepatol. 2018 Jan;33(1):270-276
pubmed: 28464337
Endocr J. 2018 Mar 28;65(3):373-381
pubmed: 29434074
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Int J Environ Res Public Health. 2019 Jun 21;16(12):
pubmed: 31234281
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Am J Clin Nutr. 1993 Oct;58(4):489-96
pubmed: 8379504
Eur J Clin Nutr. 2018 Jan;72(1):117-123
pubmed: 28901337
Am J Clin Nutr. 2021 May 8;113(5):1265-1274
pubmed: 33564868
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22
pubmed: 25267215
Stat Med. 2010 Apr 30;29(9):1037-57
pubmed: 20087875
Int J Epidemiol. 2022 Oct 13;51(5):e295-e302
pubmed: 34897450
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Food Funct. 2021 Jan 21;12(2):442-465
pubmed: 33325948
JAMA Netw Open. 2022 Mar 1;5(3):e222092
pubmed: 35285920
Am J Clin Nutr. 2015 Jun;101(6):1144-54
pubmed: 25904601
PLoS One. 2017 Feb 2;12(2):e0171502
pubmed: 28152105
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2524-2532.e2
pubmed: 34752964
Children (Basel). 2021 Apr 08;8(4):
pubmed: 33917875
Crit Rev Food Sci Nutr. 2017 Jan 2;57(1):152-162
pubmed: 26596639
Nutrients. 2019 Feb 28;11(3):
pubmed: 30823422
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
Am J Clin Nutr. 2019 Jul 1;110(1):221-232
pubmed: 31172169
Nat Rev Endocrinol. 2022 Apr;18(4):205-218
pubmed: 35064240
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Medicine (Baltimore). 2015 Oct;94(40):e1682
pubmed: 26448014
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
BMJ Open. 2018 Jul 30;8(7):e020228
pubmed: 30061433
Eur J Nutr. 2016 Nov;55(Suppl 2):25-43
pubmed: 27900447
Nutr J. 2013 Jun 07;12:75
pubmed: 23758629
Nutrients. 2019 Mar 16;11(3):
pubmed: 30884834
J Clin Epidemiol. 1997 May;50(5):541-6
pubmed: 9180646
Int J Epidemiol. 2019 Apr 1;48(2):387-388o
pubmed: 30476123
J Hepatol. 2015 Aug;63(2):462-9
pubmed: 26055949
Biomed Pharmacother. 2020 Nov;131:110795
pubmed: 33152951
Am Heart J. 2010 Apr;159(4):539-546.e2
pubmed: 20362710